MCID: BCT002
MIFTS: 56

Bacterial Vaginosis

Categories: Reproductive diseases

Aliases & Classifications for Bacterial Vaginosis

MalaCards integrated aliases for Bacterial Vaginosis:

Name: Bacterial Vaginosis 12 77 56 3 15 64 17 74
Vaginosis, Bacterial 45

Classifications:



External Ids:

Disease Ontology 12 DOID:3385
MeSH 45 D016585
NCIt 51 C116973
SNOMED-CT 69 85569008
UMLS 74 C0085166

Summaries for Bacterial Vaginosis

PubMed Health : 64 About bacterial vaginosis: In bacterial vaginosis (sometime abbreviated as BV) much larger numbers of bacteria grow inside of the vagina than would normally just be there. This increase in bacteria is usually not dangerous and it often goes unnoticed, but it can cause a strong-smelling vaginal discharge and be very unpleasant. It also increases the risk of a vaginal infection. Antibiotics can provide effective treatment.

MalaCards based summary : Bacterial Vaginosis, also known as vaginosis, bacterial, is related to trichomoniasis and vaginitis. An important gene associated with Bacterial Vaginosis is PEPD (Peptidase D), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Acetylcysteine and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and bone, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A vaginitis that is characterized by a grayish vaginal discharge usually of foul odor and the presence of Gardnerella vaginalis.

CDC : 3 Any woman can get BV.

Wikipedia : 77 Bacterial vaginosis (BV) is a disease of the vagina caused by excessive growth of bacteria. Common... more...

Related Diseases for Bacterial Vaginosis

Diseases related to Bacterial Vaginosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)
# Related Disease Score Top Affiliating Genes
1 trichomoniasis 31.6 CXCL8 LAP3
2 vaginitis 31.3 CXCL8 DEFB4A IL1B IL6 LAP3 PRF1
3 cervicitis 30.8 CXCL8 DEFB4A
4 endometritis 30.6 IL1B IL6 TNF
5 vulvovaginal candidiasis 30.3 DEFB4A MBL2 TLR2
6 scabies 29.9 CXCL8 IL1A MBL2
7 placenta disease 29.9 CXCL8 IL1B IL6
8 cytomegalovirus infection 29.7 CXCL8 IL1B IL6 TNF
9 chlamydia 29.7 CXCL8 IL1A IL1B IL6 TLR2 TLR4
10 cystitis 29.6 CXCL8 IL6 TLR4 TNF
11 oral candidiasis 29.6 CXCL8 DEFB4A IL1A
12 cerebral palsy 29.5 IL1B IL6 MBL2 TNF
13 peritonitis 29.5 CXCL8 IL1B IL6 TLR2 TNF
14 cystic fibrosis 29.4 CXCL8 DEFB4A MBL2 TLR4
15 chorioamnionitis 29.4 CXCL8 IL1A IL1B IL6 TLR4 TNF
16 arthritis 29.3 CXCL8 IL1A IL1B IL6 TNF
17 lung disease 28.8 CXCL8 IL1B IL6 MBL2 TLR2 TNF
18 periodontal disease 28.4 CXCL8 DEFB4A IL1A IL1B IL6 TLR2
19 vaginal discharge 11.6
20 candidiasis 10.7
21 human immunodeficiency virus infectious disease 10.5
22 peptic esophagitis 10.4 CXCL8 IL1B
23 campylobacteriosis 10.4 IL1B TLR4
24 actinic prurigo 10.4 IL1B TNF
25 retinitis pigmentosa 60 10.4 IL1B TNF
26 kashin-beck disease 10.4 IL1B TNF
27 burns 10.4 IL1B TNF
28 jejunoileitis 10.4 IL1B TNF
29 cerebral artery occlusion 10.4 IL1B TNF
30 pelvic inflammatory disease 10.4
31 herpes simplex 10.4
32 cervical intraepithelial neoplasia 10.4
33 staphylococcal toxic shock syndrome 10.4 IL1B TNF
34 superficial urinary bladder cancer 10.4 CXCL8 TLR4
35 pouchitis 10.4 CXCL8 TLR4
36 tungiasis 10.4 CXCL8 TNF
37 cardiac sarcoidosis 10.4 CXCL8 TNF
38 clonorchiasis 10.4 CXCL8 TNF
39 infertility 10.4
40 chronic follicular conjunctivitis 10.4 IL1A IL1B
41 cardiac rupture 10.4 CXCL8 PRF1
42 leukoregulin 10.4 CXCL8 IL1A
43 macrophage activation syndrome 10.3 PRF1 TNF
44 systemic onset juvenile idiopathic arthritis 10.3 PRF1 TNF
45 skin conditions 10.3 IL1A TNF
46 chronic graft versus host disease 10.3 IL1A TNF
47 neurosyphilis 10.3 CXCL8 TLR2
48 mycobacterium kansasii 10.3 CXCL8 TLR2
49 mycobacterium marinum 10.3 CXCL8 TLR2
50 acute cervicitis 10.3 TLR2 TLR4

Graphical network of the top 20 diseases related to Bacterial Vaginosis:



Diseases related to Bacterial Vaginosis

Symptoms & Phenotypes for Bacterial Vaginosis

MGI Mouse Phenotypes related to Bacterial Vaginosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 IL1A IL1B IL6 PEPD PRF1 TLR2
2 hematopoietic system MP:0005397 9.97 IL1A IL1B IL6 MBL2 PEPD PRF1
3 homeostasis/metabolism MP:0005376 9.91 IL1A IL1B IL6 MBL2 PEPD PRF1
4 immune system MP:0005387 9.85 IL1A IL1B IL6 LAP3 MBL2 PEPD
5 integument MP:0010771 9.56 IL1A IL1B IL6 PEPD PRF1 TLR2
6 neoplasm MP:0002006 9.17 IL1A IL1B IL6 PRF1 TLR2 TLR4

Drugs & Therapeutics for Bacterial Vaginosis

PubMedHealth treatment related to Bacterial Vaginosis: 64

Symptomatic bacterial vaginosis is usually treated using antibiotics to kill the germs. Treatments are available in tablet form or as a suppository or cream for direct application.Another treatment option is suppositories or capsules containing living lactic acid bacteria. These treatments are designed to protect the vaginal flora and restore the correct balance. There is not yet enough evidence on the benefits of this method.Some women also try things like putting tampons that have been soaked in tea tree oil or natural yogurt in their vagina to create a more acidic environment for the vaginal flora, but there has not yet been any research about how effective or safe these kinds of home remedies are.

Drugs for Bacterial Vaginosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 443-48-1 4173
3
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 18323-44-9 29029
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 22916-47-8 4189
5
Clotrimazole Approved, Vet_approved Phase 4,Phase 3 23593-75-1 2812
6
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3 57-63-6 5991
7
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
8
Etonogestrel Approved, Investigational Phase 4,Phase 2,Phase 3 54048-10-1 6917715 40976
9
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1 28014-46-2
10
Desogestrel Approved Phase 4,Phase 2,Phase 3 54024-22-5 40973
11
Tinidazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 19387-91-8 5479
12
Progesterone Approved, Vet_approved Phase 4,Not Applicable 57-83-0 5994
13
Nystatin Approved, Vet_approved Phase 4,Phase 3 1400-61-9 11953884
14
Azithromycin Approved Phase 4,Phase 2,Phase 3,Not Applicable 83905-01-5 447043 55185
15
Neomycin Approved, Vet_approved Phase 4,Phase 3 1404-04-2 8378
16
Polihexanide Approved, Investigational Phase 4 28757-47-3
17
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
18
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
19
Secnidazole Approved Phase 4,Phase 3 3366-95-8
20
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
21
Norethindrone Approved Phase 4 68-22-4 6230
22
Chlorquinaldol Approved Phase 4 72-80-0
23
Norethindrone enanthate Experimental Phase 4 3836-23-5
24 Antiviral Agents Phase 4,Not Applicable
25 Expectorants Phase 4
26 N-monoacetylcystine Phase 4
27 Free Radical Scavengers Phase 4
28 Protective Agents Phase 4,Phase 2
29 Antidotes Phase 4
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
32 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
33 Respiratory System Agents Phase 4
34 Antioxidants Phase 4
35 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
36 cysteine Phase 4
37 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
38 Clindamycin palmitate Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
39 Acidophilus Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Clindamycin phosphate Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
41 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
43 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
46 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
47 Antitubercular Agents Phase 4,Not Applicable
48 Antifungal Agents Phase 4,Phase 3,Phase 2,Early Phase 1
49 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Estradiol 17 beta-cypionate Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
2 Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
3 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
4 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
5 Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
6 Treatment of Bacterial Vaginosis (BV) With Tinidazole Completed NCT00334633 Phase 4 tinidazole, metronidazole
7 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study Completed NCT00464542 Phase 4 Metronidazole
8 Treatment of Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
9 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
10 Treatment of Bacterial Vaginosis Combined With Human Lactobacilli Completed NCT01245322 Phase 4 lactobacilli
11 Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis Completed NCT00642980 Phase 4 Clindamycin;Placebo;Clindamycin
12 Safety and Tolerability of Metronidazole Gel 1.3% Completed NCT02392026 Phase 4 Metronidazole Gel
13 Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity Completed NCT02445989 Phase 4 NuvaRing
14 Examining the Impact of Tampon Use on the Vaginal Microbiota Completed NCT03346759 Phase 4
15 N-Acetyl Cysteine for Prevention of Preterm Birth Completed NCT00568113 Phase 4 acetylcysteine in arm 1
16 Clindamycin to Reduce Preterm Birth in a Low Resource Setting Completed NCT01800825 Phase 4 Clindamycin;Placebo
17 Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis Completed NCT02444481 Phase 4 Polygynax combinaison of polymyxin, Neomycin and Nystatin
18 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
19 Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
20 PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra Completed NCT00269620 Phase 4 ethinyl estradiol/etonogestrel vaginal ring;ethinyl estradiol/norelgestromin transdermal contraceptive
21 Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis Recruiting NCT03446443 Phase 4 Honghe Fujie lotion;Metronidazole Suppositories
22 Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis Recruiting NCT02042287 Phase 4 Metronidazole
23 Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
24 Probiotics as Adjuvant Treatment for Bacterial Vaginosis Recruiting NCT03894813 Phase 4 "Probiotics" and "Metronidazole";Metronidazole Vaginal
25 The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Recruiting NCT02905890 Phase 4 Norethisterone enantate
26 Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV Recruiting NCT03937869 Phase 4 Secnidazole
27 Postmenopausal Pessary Users: Estrogen Versus Trimosan Recruiting NCT03943823 Phase 4 Estrogen vaginal cream;Trimo-San vaginal gel
28 Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity Active, not recruiting NCT02432404 Phase 4 NuvaRing
29 Evaluation of Efficacy and Safety of Gynomax® XL Ovule Not yet recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
30 Colposeptine for the Treatment of Bacterial Vaginosis Terminated NCT01153958 Phase 4 Colposeptine;Metronidazole
31 Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis Unknown status NCT02173184 Phase 3
32 A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis Unknown status NCT01089348 Phase 2, Phase 3 Lactofiltrum + Metronidazole;Metronidazole
33 The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
34 Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery Unknown status NCT01152528 Phase 3
35 Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
36 Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Unknown status NCT00491270 Phase 3
37 Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections Unknown status NCT02186145 Phase 3 Association of metronidazole; nystatin and dexamethasone;Flagyl
38 Maternal Genitourinary Infections and Adverse Perinatal Outcomes Unknown status NCT01572532 Phase 3
39 Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
40 Bacterial Vaginosis Home Screening to Prevent STDs Completed NCT00667368 Phase 3 Metronidazole
41 Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis Completed NCT01471457 Phase 2, Phase 3 Trimo-San gel
42 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577537 Phase 3 1% SPL7013 Gel;Placebo
43 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577238 Phase 3 1% SPL7013 Gel;Placebo
44 Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis Completed NCT01125410 Phase 3 Dequalinium chloride;Clindamycin
45 A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02418845 Phase 3 SYM-1219;Placebo
46 Safety and Efficacy Study to Treat Bacterial Vaginosis Completed NCT01621399 Phase 3 Product 55394;Placebo Vehicle (non-treatment)
47 Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis Completed NCT03091777 Phase 3 GDC-229;Metronidazole Vaginal Gel 0.75%;Placebo
48 Lcr35® for Bacterial Vaginosis Prevention Completed NCT01160796 Phase 3 placebo;Lcr35®
49 Treatment of Bacterial Vaginosis With Oral Tinidazole Completed NCT00229216 Phase 3 Tinidazole
50 Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole Completed NCT02452866 Phase 3 SYM-1219

Search NIH Clinical Center for Bacterial Vaginosis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: vaginosis, bacterial

Genetic Tests for Bacterial Vaginosis

Anatomical Context for Bacterial Vaginosis

MalaCards organs/tissues related to Bacterial Vaginosis:

42
Testes, Colon, Bone, Skin, Lung, Breast, Cervix

Publications for Bacterial Vaginosis

Articles related to Bacterial Vaginosis:

(show top 50) (show all 1562)
# Title Authors Year
1
Reproductive outcome of patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic PRISMA review and meta-analysis. ( 29469992 )
2019
2
Parallel detection of lactobacillus and bacterial vaginosis-associated bacterial DNA in the chorioamnion and vagina of pregnant women at term. ( 29478370 )
2019
3
Description of three new Peptoniphilus species cultured in the vaginal fluid of a woman diagnosed with bacterial vaginosis: Peptoniphilus pacaensis sp. nov., Peptoniphilus raoultii sp. nov., and Peptoniphilus vaginalis sp. nov. ( 29931836 )
2019
4
A Prospective Cohort Study of the Association Between Body Mass Index and Incident Bacterial Vaginosis. ( 30148757 )
2019
5
Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. ( 30184181 )
2019
6
Bacterial vaginosis: a primer for clinicians. ( 30424704 )
2019
7
The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment: 2018 update. ( 30507674 )
2019
8
Results from a cross-sectional sexual and reproductive health study among school girls in Tanzania: high prevalence of bacterial vaginosis. ( 30518620 )
2019
9
Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. ( 30525953 )
2019
10
High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. ( 30624309 )
2019
11
Differential sexual network connectivity offers a parsimonious explanation for population-level variations in the prevalence of bacterial vaginosis: a data-driven, model-supported hypothesis. ( 30630481 )
2019
12
Association of human papillomavirus and bacterial vaginosis with increased risk of high-grade squamous intraepithelial cervical lesions. ( 30630884 )
2019
13
The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. ( 30638028 )
2019
14
Unveiling the role of Gardnerella vaginalis in polymicrobial Bacterial Vaginosis biofilms: the impact of other vaginal pathogens living as neighbors. ( 30670827 )
2019
15
Association between preterm delivery and bacterial vaginosis with or without treatment. ( 30679584 )
2019
16
Total and Free 25-Hydroxy-Vitamin D and Bacterial Vaginosis in Pregnant African American Women. ( 30692844 )
2019
17
Association between obesity and bacterial vaginosis as assessed by Nugent score. ( 30707966 )
2019
18
Vaginal microbiota transplantation for the treatment of bacterial vaginosis: a conceptual analysis. ( 30715301 )
2019
19
Gardnerella and Prevotella: Co-conspirators in the Pathogenesis of Bacterial Vaginosis. ( 30715397 )
2019
20
Gardnerella vaginalis and Prevotella bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis. ( 30715405 )
2019
21
Quantitation of all Four Gardnerella vaginalis Clades Detects Abnormal Vaginal Microbiota Characteristic of Bacterial Vaginosis More Accurately than Putative G. vaginalis Sialidase A Gene Count. ( 30721449 )
2019
22
Description of Janibacter massiliensis sp. nov., cultured from the vaginal discharge of a patient with bacterial vaginosis. ( 30798490 )
2019
23
Collinsella vaginalis sp. nov. strain Marseille-P2666T, a new member of the Collinsella genus isolated from the genital tract of a patient suffering from bacterial vaginosis. ( 30806613 )
2019
24
Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. ( 30837554 )
2019
25
Prognostic Indicators of Recurrence of Bacterial Vaginosis. ( 30842235 )
2019
26
Could targeting neighboring bacterial populations help combat bacterial vaginosis? ( 30854891 )
2019
27
Bacterial Vaginosis and Desquamative Inflammatory Vaginitis. ( 30865815 )
2019
28
Bacterial Vaginosis and Desquamative Inflammatory Vaginitis. Reply. ( 30865816 )
2019
29
Incubation period and risk factors support sexual transmission of bacterial vaginosis in women who have sex with women. ( 30872415 )
2019
30
Continuous versus interrupted use of vaginal probiotics plus vaginal clindamycin cream for bacterial vaginosis: a randomized controlled study. ( 30879366 )
2019
31
Combined vaginal administration of nystatin, diiodohydroxyquin, and benzalkonium chloride versus oral metronidazole for the treatment of bacterial vaginosis. ( 30895611 )
2019
32
Comparison of Amsel criteria, Nugent score, culture and two CE-IVD marked quantitative real-time PCRs with microbiota analysis for the diagnosis of bacterial vaginosis. ( 30903536 )
2019
33
Prevalence of sexually transmitted infections and bacterial vaginosis among lesbian women: systematic review and recommendations to improve care. ( 30916178 )
2019
34
Detection of ureaplasmas and bacterial vaginosis associated bacteria and their association with non-gonococcal urethritis in men. ( 30946763 )
2019
35
An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. ( 30953190 )
2019
36
Taxono-genomics description of 'Lactobacillus raoultii sp. nov.', strain Marseille-P4006T, a new Lactobacillus species isolated from the female genital tract of a patient with bacterial vaginosis. ( 31011428 )
2019
37
Treatment of bacterial vaginosis before 28 weeks of pregnancy to reduce the incidence of preterm labor. ( 31022300 )
2019
38
Does bacterial vaginosis modify the effect of hormonal contraception on HIV seroconversion. ( 31048629 )
2019
39
Association of Bacterial Vaginosis and Human Papilloma Virus Infection With Cervical Squamous Intraepithelial Lesions. ( 31065675 )
2019
40
Prevalence of bacterial vaginosis and associated risk factors in pregnant women receiving antenatal care at the Kumba Health District (KHD), Cameroon. ( 31077161 )
2019
41
Therapeutic Effects of Probiotic Clostridium Butyricum WZ001 on Bacterial Vaginosis in Mice. ( 31102489 )
2019
42
Is bacterial vaginosis a disease? ( 29177936 )
2018
43
Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. ( 29196153 )
2018
44
Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. ( 29198180 )
2018
45
'Lactobacillus raoultii' sp. nov., a new bacterium isolated from the vaginal flora of a woman with bacterial vaginosis. ( 29204281 )
2018
46
Comparisons of vaginal flora patterns among sexual behaviour groups of women: implications for the pathogenesis of bacterial vaginosis. ( 29212588 )
2018
47
Redox imbalance correlates with high Nugent score in bacterial vaginosis. ( 29239072 )
2018
48
Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples - A pilot study. ( 29293559 )
2018
49
Reply to letter to editor regarding: Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception compared to levonorgestrel-releasing intrauterine system. ( 29323559 )
2018
50
A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial Vaginosis. ( 29323627 )
2018

Variations for Bacterial Vaginosis

Expression for Bacterial Vaginosis

Search GEO for disease gene expression data for Bacterial Vaginosis.

Pathways for Bacterial Vaginosis

Pathways related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 CXCL8 DEFB4A IL1A IL1B IL6 MBL2
2
Show member pathways
13.38 CXCL8 IL1A IL1B IL6 TLR2 TLR4
3
Show member pathways
13.11 CXCL8 IL1B IL6 MBL2 TLR2 TLR4
4
Show member pathways
12.95 CXCL8 IL1B IL6 TLR2 TLR4 TNF
5
Show member pathways
12.88 CXCL8 IL1A IL1B IL6 PRF1 TNF
6
Show member pathways
12.76 CXCL8 IL1B IL6 TLR4 TNF
7
Show member pathways
12.74 IL1A IL1B IL6 TLR2 TLR4 TNF
8
Show member pathways
12.63 IL1A IL1B TLR2 TLR4 TNF
9
Show member pathways
12.63 IL1A IL1B IL6 TLR2 TLR4 TNF
10
Show member pathways
12.55 IL1A IL1B IL6 TNF
11
Show member pathways
12.35 CXCL8 DEFB4A IL1B IL6 TLR2 TNF
12
Show member pathways
12.34 CXCL8 IL1A IL1B IL6 TLR4 TNF
13
Show member pathways
12.31 IL1A IL1B TLR2 TLR4 TNF
14
Show member pathways
12.28 CXCL8 IL1A IL1B IL6 TNF
15
Show member pathways
12.28 CXCL8 IL1A IL6 TLR2 TLR4 TNF
16 12.24 IL1A IL1B IL6 TLR2 TLR4 TNF
17
Show member pathways
12.23 IL1A IL1B TLR4 TNF
18 12.23 CXCL8 IL1A IL1B IL6 TNF
19
Show member pathways
12.22 CXCL8 IL1A IL1B IL6 TLR2 TNF
20
Show member pathways
12.21 CXCL8 IL1A IL1B TLR2 TLR4
21 12.21 IL6 TLR2 TLR4 TNF
22
Show member pathways
12.16 IL1B IL6 TNF
23 12.12 CXCL8 IL1A IL6
24
Show member pathways
12.11 IL1B IL6 TLR2 TLR4 TNF
25 12.09 MBL2 TLR2 TLR4
26
Show member pathways
12.09 IL1B IL6 TLR2 TLR4 TNF
27
Show member pathways
12.06 IL1A IL1B TLR2 TLR4
28 12.05 IL1A IL1B TNF
29
Show member pathways
12.04 CXCL8 IL1A IL1B IL6
30 12.04 CXCL8 IL1A IL1B IL6 TNF
31
Show member pathways
12.02 CXCL8 DEFB4A IL1B IL6 TLR2 TLR4
32 12.01 IL1A IL1B TNF
33 11.99 CXCL8 IL1A IL1B IL6
34 11.99 CXCL8 IL1A IL1B IL6 TLR4 TNF
35 11.96 CXCL8 IL1B TLR4 TNF
36 11.96 CXCL8 IL1A IL1B IL6 TNF
37 11.95 IL1A IL1B IL6 TNF
38 11.94 IL1B IL6 TNF
39 11.88 CXCL8 IL1A IL1B IL6 TLR4
40
Show member pathways
11.87 CXCL8 IL6 TLR4
41 11.83 CXCL8 IL1B IL6 TLR2 TLR4 TNF
42 11.76 IL1B IL6 TNF
43 11.75 CXCL8 IL1B IL6 TNF
44 11.74 IL1B IL6 TNF
45 11.68 CXCL8 IL1A IL1B IL6 TLR4 TNF
46
Show member pathways
11.67 CXCL8 IL1A IL1B IL6 TNF
47 11.61 IL1A TLR4 TNF
48 11.6 IL1B TLR2 TLR4 TNF
49 11.56 IL1A IL1B IL6
50 11.56 IL1A IL1B IL6 TNF

GO Terms for Bacterial Vaginosis

Cellular components related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 CXCL8 DEFB4A IL1A IL1B IL6 MBL2
2 extracellular region GO:0005576 9.23 CXCL8 DEFB4A IL1A IL1B IL6 MBL2

Biological processes related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 IL1A IL1B IL6 TLR2 TLR4 TNF
2 defense response to bacterium GO:0042742 9.94 DEFB4A MBL2 TLR4 TNF
3 cytokine-mediated signaling pathway GO:0019221 9.93 CXCL8 IL1A IL1B IL6 TNF
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.9 IL1B TLR4 TNF
5 response to lipopolysaccharide GO:0032496 9.9 IL1B TLR2 TLR4
6 positive regulation of angiogenesis GO:0045766 9.89 CXCL8 IL1A IL1B
7 defense response GO:0006952 9.89 CXCL8 DEFB4A TNF
8 cellular response to lipopolysaccharide GO:0071222 9.88 CXCL8 IL1B IL6 TLR4 TNF
9 activation of MAPK activity GO:0000187 9.87 IL1B TLR4 TNF
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.87 IL1B IL6 TNF
11 defense response to Gram-negative bacterium GO:0050829 9.85 DEFB4A IL6 TLR4
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 IL1B IL6 TLR2 TLR4 TNF
13 positive regulation of JNK cascade GO:0046330 9.84 IL1B TLR4 TNF
14 positive regulation of inflammatory response GO:0050729 9.84 TLR2 TLR4 TNF
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 IL1B TLR2 TLR4 TNF
16 positive regulation of interferon-gamma production GO:0032729 9.79 IL1B TLR4 TNF
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 IL1B TLR4 TNF
18 positive regulation of phagocytosis GO:0050766 9.75 IL1B MBL2 TNF
19 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.74 IL1A IL1B TNF
20 positive regulation of interleukin-12 production GO:0032735 9.73 TLR2 TLR4
21 positive regulation of interleukin-10 production GO:0032733 9.72 TLR2 TLR4
22 negative regulation of neurogenesis GO:0050768 9.72 IL1B IL6 TNF
23 defense response to Gram-positive bacterium GO:0050830 9.72 DEFB4A IL6 MBL2 TLR2 TNF
24 microglial cell activation GO:0001774 9.71 TLR2 TNF
25 embryonic digestive tract development GO:0048566 9.71 CXCL8 TNF
26 negative regulation of lipid catabolic process GO:0050995 9.71 IL1B TNF
27 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.71 IL1B TNF
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 IL1B TNF
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.71 IL1B TLR2 TLR4 TNF
30 negative regulation of growth of symbiont in host GO:0044130 9.7 MBL2 TNF
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL1B TNF
32 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 TLR2 TLR4
33 positive regulation of glial cell proliferation GO:0060252 9.7 IL1B IL6 TNF
34 inflammatory response GO:0006954 9.7 CXCL8 IL1A IL1B IL6 TLR2 TLR4
35 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.69 IL1A IL1B
36 regulation of cytokine secretion GO:0050707 9.69 TLR2 TLR4
37 I-kappaB phosphorylation GO:0007252 9.68 TLR2 TLR4
38 response to molecule of bacterial origin GO:0002237 9.68 CXCL8 TLR2
39 cellular response to lipoteichoic acid GO:0071223 9.68 TLR2 TLR4
40 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.68 TLR4 TNF
41 negative regulation of lipid storage GO:0010888 9.67 IL6 TNF
42 positive regulation of interleukin-8 production GO:0032757 9.67 IL1B TLR2 TLR4 TNF
43 positive regulation of chemokine biosynthetic process GO:0045080 9.66 IL1B TNF
44 ectopic germ cell programmed cell death GO:0035234 9.65 IL1A IL1B
45 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
46 response to glucocorticoid GO:0051384 9.64 IL6 TNF
47 positive regulation of fever generation GO:0031622 9.63 IL1B TNF
48 sequestering of triglyceride GO:0030730 9.62 IL1B TNF
49 positive regulation of neuroinflammatory response GO:0150078 9.61 IL1B IL6 TNF
50 fever generation GO:0001660 9.59 IL1A IL1B

Molecular functions related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.16 IL1A IL1B
2 cytokine activity GO:0005125 9.02 CXCL8 IL1A IL1B IL6 TNF
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Bacterial Vaginosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....